ADAPTIVE BIOTECHNOLOGIES CORPORATION Increase (Decrease) in Accounts Receivable
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Increase (Decrease) in Accounts Receivable of -$852.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $1.20M, a 70.66% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$2.05M, a 209.98% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $5.54M, a 516.69% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $536.00K, a 89.70% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in accounts receivable for fiscal 2025 was $8.65M, a 130.93% increase from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in accounts receivable for fiscal 2024 was $3.74M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in accounts receivable for fiscal 2023 was -$2.03M, a 108.97% decline from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in accounts receivable for fiscal 2022 was $22.65M, a 207.63% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$852.00K 10-Q · filed 2026-08-04 | $4.69M derived: sum of 3 quarters · filed 2026-08-04 | $5.23M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$2.05M 10-Q · filed 2026-05-05 | $3.49M derived: sum of 2 quarters · filed 2026-05-05 | $4.03M derived: sum of 3 quarters · filed 2026-05-05 | $4.73M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $5.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.08M derived: sum of 2 quarters · filed 2026-02-26 | $6.78M derived: sum of 3 quarters · filed 2026-08-04 | $8.65M 10-K · filed 2026-02-26 |
| 2025-09-30 | $536.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.24M derived: sum of 2 quarters · filed 2026-08-04 | $3.10M 10-Q · filed 2025-11-05 | $4.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $702.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $2.57M 10-Q · filed 2026-08-04 | $3.46M derived: sum of 3 quarters · filed 2026-08-04 | $8.67M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $1.86M 10-Q · filed 2026-05-05 | $2.76M derived: sum of 2 quarters · filed 2026-05-05 | $7.97M derived: sum of 3 quarters · filed 2026-05-05 | $1.56M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $899.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.10M derived: sum of 2 quarters · filed 2026-02-26 | -$308.00K derived: sum of 3 quarters · filed 2026-02-26 | $3.74M 10-K · filed 2026-02-26 |
| 2024-09-30 | $5.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.21M derived: sum of 2 quarters · filed 2025-11-05 | $2.85M 10-Q · filed 2025-11-05 | $9.61M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$6.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$2.36M 10-Q · filed 2025-08-05 | $4.41M derived: sum of 3 quarters · filed 2026-02-26 | $4.07M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $4.05M 10-Q · filed 2025-05-01 | $10.82M derived: sum of 2 quarters · filed 2026-02-26 | $10.48M derived: sum of 3 quarters · filed 2026-02-26 | $11.11M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $6.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.43M derived: sum of 2 quarters · filed 2026-02-26 | $7.05M derived: sum of 3 quarters · filed 2026-02-26 | -$2.03M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$334.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $287.00K derived: sum of 2 quarters · filed 2024-11-07 | -$8.80M 10-Q · filed 2024-11-07 | $4.71M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $621.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$8.46M 10-Q · filed 2024-08-01 | $5.04M derived: sum of 3 quarters · filed 2025-03-03 | $7.88M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$9.09M 10-Q · filed 2024-05-07 | $4.42M derived: sum of 2 quarters · filed 2025-03-03 | $7.26M derived: sum of 3 quarters · filed 2025-03-03 | $8.45M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $13.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $16.34M derived: sum of 2 quarters · filed 2025-03-03 | $17.54M derived: sum of 3 quarters · filed 2025-03-03 | $22.65M 10-K · filed 2025-03-03 |
| 2022-09-30 | $2.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.03M derived: sum of 2 quarters · filed 2023-11-09 | $9.14M 10-Q · filed 2023-11-09 | $9.43M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $6.30M 10-Q · filed 2023-08-02 | $6.59M derived: sum of 3 quarters · filed 2024-02-29 | $9.54M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $5.11M 10-Q · filed 2023-05-03 | $5.40M derived: sum of 2 quarters · filed 2024-02-29 | $8.34M derived: sum of 3 quarters · filed 2024-02-29 | $2.76M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $287.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $3.23M derived: sum of 2 quarters · filed 2024-02-29 | -$2.35M derived: sum of 3 quarters · filed 2024-02-29 | $7.36M 10-K · filed 2024-02-29 |
| 2021-09-30 | $2.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$2.63M derived: sum of 2 quarters · filed 2022-11-03 | $7.08M 10-Q · filed 2022-11-03 | $5.26M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | -$5.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $4.13M 10-Q · filed 2022-08-03 | $2.32M derived: sum of 3 quarters · filed 2023-02-14 | $6.26M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $9.71M 10-Q · filed 2022-05-04 | $7.90M derived: sum of 2 quarters · filed 2023-02-14 | $11.84M derived: sum of 3 quarters · filed 2023-02-14 | $10.37M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | -$1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $2.13M derived: sum of 2 quarters · filed 2023-02-14 | $665.00K derived: sum of 3 quarters · filed 2023-02-14 | -$2.61M 10-K · filed 2023-02-14 |
| 2020-09-30 | $3.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $2.48M derived: sum of 2 quarters · filed 2021-11-03 | -$802.00K 10-Q · filed 2021-11-03 | $2.62M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | -$1.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$4.75M 10-Q · filed 2021-08-04 | -$1.33M derived: sum of 3 quarters · filed 2022-02-15 | $626.00K derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | -$3.28M 10-Q · filed 2021-05-05 | $141.00K derived: sum of 2 quarters · filed 2022-02-15 | $2.09M derived: sum of 3 quarters · filed 2022-02-15 | $5.28M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $3.42M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $5.37M derived: sum of 2 quarters · filed 2022-02-15 | $8.56M derived: sum of 3 quarters · filed 2022-02-15 | $7.82M 10-K · filed 2022-02-15 |
| 2019-09-30 | $1.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $5.14M derived: sum of 2 quarters · filed 2020-11-10 | $4.40M 10-Q · filed 2020-11-10 | -$3.16M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $3.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $2.44M 10-Q · filed 2020-08-10 | -$5.12M derived: sum of 3 quarters · filed 2021-02-24 | $2.83M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | -$741.00K 10-Q · filed 2020-05-12 | -$8.30M derived: sum of 2 quarters · filed 2021-02-24 | -$351.00K derived: sum of 3 quarters · filed 2021-02-24 | |
| 2018-12-31 | -$7.56M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $390.00K derived: sum of 2 quarters · filed 2021-02-24 | -$775.00K 10-K · filed 2021-02-24 | |
| 2018-09-30 | $7.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $6.79M 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | -$1.17M 10-Q · filed 2019-08-13 | |||
| 2017-12-31 | $2.43M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |